Biosimilars are eating Humira's lunch

Ajouter une nouvelle offre d'emploi Sağlıklı Yaşam

2026-04-16 09:53:44 -

Humira's patent expired in 2016, but AbbVie fought off biosimilars for years. Now, the floodgates have opened. The US tumor necrosis factor alpha inhibitors market forecast shows that biosimilars will capture over 50% of the market by 2030, driving prices down. In 2023, the first biosimilar of Humira (Amjevita) launched at a 50% discount. That's huge for patients with high...

0 Commentaires 0 Parts 34 Vue 0 Aperçu